Regeneron and Sanofi Report the US FDA Acceptance of sBLA for Priority Review of Dupixent to Treat Eosinophilic Esophagitis in Children Aged 1-11Years
- The US FDA has accepted the sBLA for Priority Review of Dupixent to treat children aged 1-11yrs. with EoE. The US FDA’s decision is expected in Jan 2024
- The sBLA was based on the P-III (EoE KIDS) trial (Parts A and B) evaluating Dupixent in children aged 1-11yrs. with EoE. In Part A, the trial met its 1EPs & showed that patients achieved histological disease remission at 16wks. for tiered dosing regimens based on body weight
- Part B, an active treatment extension period showed that Dupixent maintained histologic remission for 52wks. & led to increases in body weight for the age percentile. The safety results were consistent with the known safety profile of Dupixent in EoE indication for children and adults aged ≥12yrs.
Ref: Globenewswire | Image: Regeneron
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.